Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs eBay Inc (EBAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs eBay Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while eBay Inc trades at $106.26 (market cap $47.93B). The key difference: eBay Inc is far larger — about 5.1× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and eBay Inc pays a 1.15% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | EBAY | |
|---|---|---|
Market Cap | $9.39B | $47.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $356.25 | $118.96 |
52-Week Low | $241.71 | $79.41 |
Enterprise Value | $9.14B | $51.75B |
Volume | — | 5,186,418 |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
EBAY trades at $111.98, up 1.67% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust fundamentals, including a net income margin of 18.57% and ROE of 47.38%, supported by revenue growth to $11.10B in 2025. Recent news highlights potential partnership talks with GameStop after a withdrawn $56B bid, adding volatility but strategic interest.
Outlook is positive with a consensus price target of $119.85, indicating ~7% upside, driven by earnings momentum and focus category growth. Risks include competitive pressures in e-commerce and market sensitivity to merger speculation. Investors may find value in sustained profitability and analyst buy ratings, though monitor execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →
